Updated Saskatoon Prostate Cancer Support Group Website:
www.pcssaskatoon.ca
#ProstateCancer #ProstateCancerSupport
#ProstateCancerAwareness
@prostatecanceruk.bsky.social @prostatepuncher.bsky.social @apccc.bsky.social @ubcmedicine.bsky.social @joycevance.bsky.social

William K. Oh Awarded EveryGrant by Conquer Cancer - Yale Cancer Center - OncoDaily William K. Oh Awarded EveryGrant by Conquer Cancer - Yale Cancer Center / cancer, OncoDaily, Oncology, prostate cancer, William K. Oh, Yale Cancer Center

Yale Cancer Center - William Oh Awarded EveryGrant by Conquer Cancer

@yalecancer.bsky.social @williamohmd.bsky.social

oncodaily.com/voices/yale-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ProstateCancer

We invite submissions to the Special Collection Advances in Biomarkers for Genitourinary Cancers in Ther Adv Med Onc. We welcome studies on diagnostic, prognostic, predictive and molecular biomarkers across GU malignancies.
buff.ly/sQgaDWS
#GUcancer #Oncology #ProstateCancer #BladderCancer

Conquer Cancer’s EveryGrant announces Quality Improvement grants, funded by Pfizer, to leverage technology to improve biomarker-driven testing and treatment Current clinical guidelines for multiple cancers, including colon, prostate, and lung cancers, recommend biomarker testing to properly guide treatment decisions. However, utilization and efficiency of...

We're pleased to announce @williamohmd.bsky.social has been awarded an EveryGrant from the #ConquerCancerFoundation to support “Optimizing Biomarker and Genomic Testing in #ProstateCancer: Identifying Gaps and Implementing Quality Improvement Solutions.”
conquer.org/news/conquer...

🎙️Simply Oncology Podcast on PSMA Lutetium in #ProstateCancer out now with the superb Dr Amy Eccles
🎙️ Prostate Cancer Awareness Month we discuss➡️ future of PSMA lutetium & other molecular radiotherapy targets in PCa

Enjoy

Part 2 of 2

@eururoloncol.bsky.social @oncoalert.bsky.social
@uroweb.org

ORIC Pharmaceuticals to Report Prostate Trial Data Tuesday ORIC (NASDAQ: ORIC) will publish prostate cancer cohort data on Tuesday, Mar 31, 2026 (Investing.com); this binary readout could move valuation by ±25% or more.

ORIC Pharmaceuticals to Report Prostate Trial Data Tuesday: ORIC (NASDAQ: ORIC) will publish prostate cancer cohort data on Tuesday, Mar 31, 2026 (Investing.com); this binary readout could move valuation by ±25% or… 👈 Read full analysis #ORIC #ProstateCancer #Biotech #ClinicalTrials #Pharmaceuticals

Four graphs show cumulative incidence differences between users of Sodium-Glucose Cotransporter 2 Inhibitors and all other patients. X axes represent follow-up time in months, y axes show cumulative incidence difference in %. The graphs depict outcomes for different conditions.

Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/41ApOb2

Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial - British Journal of Cancer British Journal of Cancer - Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial

Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for #ProstateCancer: the MANCAN2 randomized controlled trial. @VelindreCS www.nature.com/articles/s41...

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer | NEJM Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is su...

Transdermal Estradiol Patches in Locally Advanced #ProstateCancer. www.nejm.org/doi/full/10....

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer Background Poly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous re...

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant #ProstateCancer. jitc.bmj.com/content/14/3...

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14) In SAKK08/14, adding metformin to enzalutamide did not significantly improve oncological outcomes in unselected men with metastatic castration-resistant prostate cancer. Metformin seemed to benefit pa...

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant #ProstateCancer: A Randomized Phase 2 Trial (SAKK 08/14). euoncology.europeanurology.com/article/S258...

More effective prostate cancer screening: Closing the gap with breast cancer Volume 13, Issue 12 | March 26, 2026

ALSO IN THIS ISSUE
Diagnosing #neurodegenerativedisease by looking at the eye?
A simple #nasalswab for Alzheimer’s disease

open.substack.com/pub/sensitiv...

#sensitiveandspecific #diagnostics #genomics #innovationinhealthcare #prostatecancer #cancerscreening #breastcancer #alzheimers

A new RNA–chromatin interaction mechanism behind prostate cancer progression just came into focus. ➡️ Read our new blog to dive into the full story: bit.ly/40WOryv

🔍 If you’re studying epigenetics, RNA biology, or cancer mechanisms, this is must-read.
______
#Epigenetics #ProstateCancer #ActiveMotif

What an amazing set of studies to have worked on - and what a fabulous legacy!

#ProudestOf #ProstateCancer #UKCTUNetwork

Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial − two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacing Prostate cancer has been and continues to be the most prevalent non-skin cancer among men with rates of clinically significant disease increasing [1]. Radiation therapy has long been known to be an ef...

Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial − two-fraction stereotactic radiotherapy for localized #ProstateCancer using rectal spacing. www.thegreenjournal.com/article/S016...

As a medical school professor, I can tell you: the textbooks got this one wrong. We taught that once you have prostate cancer, exercise is nice but optional.... https://www.nature.com/articles/s41391-026-01105-8

#ProstateCancer #ExerciseIsMedicine #MetabolicHealth #Longevity #HealthLongevitySecrets

💡 Why does it matter?

These insights help identify good practices, as well as key gaps and barriers in real clinical settings, supporting better communication and patient engagement.

#HealthLiteracy #ProstateCancer

HRT patches effective for controlling locally advanced prostate cancer Oestradiol patches normally used as HRT treatment for the menopause are just as effective for controlling locally advanced prostate cancer as hormone injections, a large UK trial has found.

HRT patches are effective for controlling locally advanced prostate cancer, a study has found #doctors #prostatecancer www.doctors.net.uk/news/hrt-pat...

Prostate cancer: treatment and risk of metastasis #cancer #prostatitis #prostatecancer #prostate Prostate cancer: treatment and risk of metastasis #cancer #prostatitis #prostatecancer #prostate

Prostate cancer: treatment and risk of metastasis #cancer #prostatitis #prostatecancer #prostate ... Continue to: www.facebook.com/reel/1769298...

Novel Therapeutic Interventions For The Treatment Of Prostate Cancer Prostate cancer is the most common cancer that affects the male population. National Institute for Health and Care Excellence (2026) revealed that prostate cancer accounted for 46000 cases in Engla…

Good evening everyone!

There are ongoing efforts to improve diagnosis and develop therapeutic strategies to enhance overall survival for patients with prostate cancer.

Please click here to find out more:
farahsaeed.org/2026/03/25/n...

#prostatecancer

Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers | CancerNetwork Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

🧬 Dr. Benjamin Garmezy discusses emerging prostate cancer strategies—highlighting molecular glues & T‑cell engagers—in a new CancerNetwork interview.
🔗 www.cancernetwork.com/view/emergin...
#ProstateCancer #Oncology #PrecisionMedicine #SCRI

Portrait of a smiling person wearing a purple top and pearl earrings, with a blurred greenery background.

At tonight's 5:30 PM #ProstateCancer #SupportGroup, we will discuss (hormone) androgen deprivation therapy (ADT). You'll learn about vetted integrative modalities that can address some of the symptoms associated with ADT with Suzanne McMurry ND, FABNO. Register and join here: https://bit.ly/4jo7muq

No benefit of post-surgery hormone therapy for many prostate cancer patients Adding hormone therapy to postoperative radiotherapy after radical prostatectomy does not significantly improve overall survival for most patients with prostate cancer.

#MedNews - Adding hormone therapy to postoperative #radiotherapy after radical prostatectomy does not significantly improve overall survival for most patients with #ProstateCancer.

Full story 👉 buff.ly/84rsKVM

#OncSky

The Importance of Prostate Cancer Screening for Men The blog discusses the importance of prostate cancer screening, illustrated by Dave’s story, who was diagnosed early after a routine checkup. It explains what prostate cancer is, why early de…

Check out the newest post on geneIQ website.
#prostatecancer #cancerscreening

geneiq.org/2026/03/25/t...

Scientific Paper published in European Journal of Radiology Artificial Intelligence titled: In prostate cancer diagnosis, a deep learning model shows increased susceptibility to MRI quality variations compared to radiologists. Written by Pooch et al.

Could MRI image quality limit the performance of deep learning models in #ProstateCancer diagnosis?

Validated by data from our funded research, Prof Ivo Schoots & Eduardo Pooch unveil new findings in European Journal of Radiology Artificial Intelligence.

Grab a ☕ & read: doi.org/10.1016/j.ej...

Construction industry one of most vulnerable to prostate cancer due to high proportion of male workers The Chartered Institute of Building has teamed up with leading men’s health charity, Prostate Cancer UK.

CIOB is supporting Prostate Cancer UK for #ProstateCancer Awareness Month by sharing their free & confidential risk checker which takes just 30 seconds to complete. We'd like male workers across the #construction industry to go online to find out more.
#BuiltEnvironment #building #MensHealth #CIOB

PROTAC technology for prostate cancer treatment
www.scienceopen.com/hosted-docum...
#PROTAC #ProstateCancer #TargetedTherapy #ProteinDegradation #Oncology

A Northwestern Medicine study published in the Journal of Clinical Investigation has uncovered a connection between a well-known cancer-related protein and a major RNA modification process, which may inform new treatment strategies against #ProstateCancer.
https://bit.ly/3NmHmnV

🚨 Call for Papers!
Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open.
🗓 Deadline: 6 Nov 2026
🔗 Submit here: buff.ly/sQgaDWS
#Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer

GI Innovation and J&J Team Up to Tackle Advanced Prostate Cancer - AktieGo GI Innovation and Johnson & Johnson are testing a combination immunotherapy in metastatic castration-resistant prostate cancer. Here's what the trial means.

GI Innovation & J&J are teaming up for a Phase 1b trial combining immune-boosting GI-102 with J&J’s bispecific T-cell engager pasritamig.
Excited or skeptical? Drop your thoughts!
aktiego.com/sectors/biot...

#ProstateCancer #Immunotherapy #CancerResearch #GIInnovation #Oncology